Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.58 |
| ▸ | CA2 | P00918 | 4/20 | 0.58 |
| ▸ | CA7 | P43166 | 3/20 | 0.58 |
| ▸ | CA9 | Q16790 | 3/20 | 0.58 |
| ▸ | CA12 | O43570 | 2/20 | 0.58 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.58 |
| ▸ | CA4 | P22748 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL714204 | 0.87 | CA1 (0.50) | CA1CA2CA7CA9CA12 | |
| SCHEMBL5394326 | 0.83 | CA12 (0.46) | CA1CA2CA7CA9CA12 | |
| SCHEMBL4401750 | 0.83 | NFE2L2 (0.47) | CA1CA2CA7CA9CA12 | |
| SCHEMBL23521027 | 0.79 | IDO1 (0.48) | CA1CA2CA7CA9CA12 | |
| SCHEMBL8577809 | 0.79 | LPAR1 (0.47) | CA1CA2CA7CA9CA12 | |
| SCHEMBL2292046 | 0.78 | L3MBTL1 (0.44) | CA1CA2CA7CA9CA12 | |
| SCHEMBL21830399 | 0.78 | CYP2A6 (0.44) | CA1CA2CA7CA9CA12 | |
| SCHEMBL16599722 | 0.78 | POLB (0.49) | CA1CA2CA7CA9CA12 | |
| SCHEMBL28148154 | 0.75 | CA1 (0.65) | CA1CA2CA7CA9CA12 | |
| SCHEMBL54887 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 418 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114106044-B | Binuclear pyridine phosphine base, full-acrylate thermoplastic elastomer and preparation method thereof | 吉林大学 | 2023-04-25 | — | — | CN | claimed |
| CN-114106044-A | Binuclear pyridine phosphine base, full-acrylate thermoplastic elastomer and preparation method thereof | 吉林大学 | 2022-03-01 | — | — | CN | claimed |
| CN-101130579-B | Domino catalytic system for producing branching polythene and use method of the same | UNIV HEBEI TECHNOLOGY | 2010-06-23 | — | — | CN | claimed |
| EP-1651958-B1 | NOVEL CHEMILUMINESCENT COMPOUNDS AND THEIR USE | ROCHE DIAGNOSTICS GMBH (DE) | 2010-06-16 | — | — | EP | claimed |
| CN-101130579-A | Domino catalytic system producing branching polythene and use method of the same | UNIV HEBEI TECHNOLOGY (CN) | 2008-02-27 | — | — | CN | claimed |
| EP-1383750-B1 | UREA DERIVATIVES AS INTEGRIN ALPHA 4 ANTAGONISTS | ALMIRALL LAB (ES) | 2007-09-26 | — | — | EP | claimed |
| EP-1664042-A1 | IMIDAZO 1,5-a PYRIDINE OR IMIDAZO 1,5-a PIPERIDINE DERIVATIVES AND THEIR USE FOR THE PREPARATION OF MEDICAMENT AGAINST 5-HT2A RECEPTOR-RELATED DISORDERS | Galapagos N.V. (BE) | 2006-06-07 | — | — | EP | claimed |
| EP-1663972-A1 | THE CLAIMED INVENTION RELATES TO NOVEL 4-PIPERIDINECARBOXAMIDE AND THE USE THEREOF FOR THE PREPARATION OF MEDICAMENTS AGAINST 5-HT2A RECEPTOR-RELATED DISORDERS | Galapagos N.V. (BE) | 2006-06-07 | — | — | EP | claimed |
| US-20050215555-A1 | Imidazo[1,5-a]pyridine serotonin (5-HT) 5-HT2A receptor antagonists such as 1-phenyl-3-[1-(2-phenylethyl)piperidin-4-yl]imidazo[1,5-a]pyridine; psychological disorders, sleep disorders, addiction, cardiovascular disorders, epilepsy, glaucoma | BLOVITRUM AB (SE) | 2005-09-29 | — | — | US | claimed |
| US-20050215589-A1 | Inhibitors of 5-HT2A receptor | BIOVITRUM AB (SE) | 2005-09-29 | — | — | US | claimed |
| CN-1157386-C | Trisubstituted 1,3,5-triazine derivatives for treatment by HIV infections | ղɭҩҵ����˾ | 2004-07-14 | — | — | CN | claimed |
| US-20020115668-A1 | Trisubstituted 1,3,5-triazine derivatives | DAEYAERT FREDERIK FRANS DESIRE (BE) | 2002-08-22 | — | — | US | claimed |
| CN-1067690-C | Catalyst system for syndiotactic polymerization, its preparing method and use thereof | CHINESE ACAD INST CHEMISTRY (CN) | 2001-06-27 | — | — | CN | claimed |
| CN-1295566-A | Trisubstituted 1,3,5-triazine derivatives for treatment by HIV infections | JANSSEN PHARMACEUTICA NV (BE) | 2001-05-16 | — | — | CN | claimed |
| EP-1066269-A1 | TRISUBSTITUTED 1,3,5-TRIAZINE DERIVATIVES FOR TREATMENT OF HIV INFECTIONS | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-01-10 | — | — | EP | claimed |
| US-6150360-A | ADMINISTERING TO A PATIENT SUFFERING FROM HUMAN IMMUNODEFICIENCY VIRUS INFECTION A TRISUBSTITUTED 1,3,5-TRIAZINE DERIVATIVE | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-11-21 | — | — | US | claimed |
| WO-1999050256-A1 | TRISUBSTITUTED 1,3,5-TRIAZINE DERIVATIVES FOR TREATMENT OF HIV INFECTIONS | JANSSEN PHARMACEUTICA N.V. (BE) | 1999-10-07 | — | — | WO | claimed |
| CN-1215735-A | Catalyst system for synthesis of syndiotactic polystyrene | CHINESE ACAD INST CHEMISTRY (CN) | 1999-05-05 | — | — | CN | claimed |
| CN-1191223-A | Catalyst system for syndiotactic polymerization, its preparing method and use thereof | CHINESE ACAD INST CHEMISTRY (CN) | 1998-08-26 | — | — | CN | claimed |
| US-5798362-A | USEFUL AS ALPHA-ADRENORECEPTOR BLOCKERS; CONDENSATION | RECORDATI S.A. CHEMICAL AND PHARMACEUTICAL COMPANY (CH) | 1998-08-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115668-A1 | Trisubstituted 1,3,5-triazine derivatives | XDH, CCR5, CXCR1 | CA1 4799/4885CA2 4527/4885CA7 4366/4885 |
| US-20050215589-A1 | Inhibitors of 5-HT2A receptor | HTR2A, HTR1A, HTR2C | CA1 3101/4885CA2 3899/4885CA7 4736/4885 |
| US-20050215555-A1 | Imidazo[1,5-a]pyridine serotonin (5-HT) 5-HT2A receptor antagonists such as 1-phenyl-3-[1-(2-phenylethyl)piperidin-4-yl]imidazo[1,5-a]pyridine; psychological disorders, sleep disorders, addiction, cardiovascular disorders, epilepsy, glaucoma | HTR1A, HTR2A, HTR5A | CA1 4741/4885CA2 2156/4885CA7 4718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.